Drug Profile
Research programme: anti-cancer therapeutics - Maxinovel Pharmaceuticals
Alternative Names: Max 2Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Maxinovel Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer